Korea - SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has been named a CES 2023 Innovation Awards Honoree for outstanding design and engineering of two wearable devices - Zero GlassesTM and Zero WiredTM.
SK Biopharmaceuticals will become the first Korean pharmaceutical company to earn such an accolade in the category of digital health. The announcement came ahead of the CES 2023, the world's most influential and biggest technology event that will be held January 5-8 in Las Vegas, Nevada.
Zero Glasses, smart glasses, and Zero Wired, a wired device connectable to mobile phones, are integrated wearable devices that can detect and forecast seizure by measuring bio-signals from brain activity, heart rhythm, and body movement.
They are compatible with SK Biopharmaceuticals' mobile application named Zero AppTM that can record and analyze bio-signal data in real time. The wearable devices can be worn comfortably in both professional and private settings.
The names of the wearable devices derive from SK Biopharmaceuticals' key mission to strive for the potential of 'zero seizures' for patients through cenobamate, an anti-seizure medication (ASM) approved by the U.S. Food and Drug Administration for the treatment of partial-onset (focal-onset) seizures in adults. It is commercially available in the U.S. under the brand name XCOPRI (cenobamate tablets) CV. SK Biopharmaceuticals operates in the U.S. through SK Life Science, a subsidiary based in New Jersey.
SK Biopharmaceuticals will showcase the wearable devices and provide an on-site demonstration at CES 2023. The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA), is an annual competition honoring outstanding design and engineering in 28 consumer technology product categories.
About SK Biopharmaceuticals
SK Biopharmaceuticals and its U.S. subsidiary SK Life Science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology.
About Cenobamate
Cenobamate is an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK life science. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the -aminobutyric acid (GABAA) ion channel.
Cenobamate is approved in the United States for the treatment of partial-onset seizures in adults and is available under the brand name XCOPRI (cenobamate tablets) CV. Cenobamate can be combined with other ASMs or used alone. The recommended initial dosage of cenobamate is 12.5 mg once-daily, with titration every two weeks; it is available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.
Cenobamate is also approved in the European Union and the United Kingdom for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with seizures that have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products and is marketed by Angelini Pharma under the brand name ONTOZRY.
Additionally, cenobamate is in clinical development in Asia. Ono Pharmaceutical and Ignis Therapeutics have the rights to develop and commercialize cenobamate in Japan and in the Greater China region, respectively. SK Biopharmaceuticals has recently entered into an exclusive licensing agreement with Endo for cenobamate in Canada.
Contact:
Email: skbpcomm@sk.com
SK BIOPHARMACEUTICALS CO., LTD. 
